Literatur
-
1
Findler G, Lavy S.
Transient hemiparesis; A rare manifestation of diphenylhydantoin toxicity.
J Neurosurg.
1979;
50
685-687
-
2
Sandyk R.
Transient hemiparesis - a rare complication of phenytoin toxicity.
Postgraduate Medical Journal.
1983;
59
601-602
-
3
Stephen L J, Maxwell J E, Brodie M J.
Transient hemiparesis with topiramate.
BMJ.
1999;
318
845
-
4
Bono A, Beghi E, Bogliun G. et al .
Antiepileptic drugs and peripheral nerve function: a multicenter screening investigation of 141 patients with chronic treatment.
Epilepsia.
1993;
34
323-331
-
5
Geraldini C, Faeda M T, Sideri G.
Anticonvulsant therapy and its possible consequences on peripheral nervous system: a neurographic study.
Epilepsia.
1984;
25
502-505
-
6
Dobkin B H.
Reversible subacute peripheral neuropathy induced by phenytoin.
Arch Neurol.
1977;
34
189-190
-
7
Yoshikawa H, Abe T, Oda Y.
Extremely acute phenytoin-induced peripheral neuropathy.
Epilepsia.
1999;
40
528-529
-
8
Ng K, Silbert P L, Edis R H.
Complete external ophthalmoplegia and asterixis with carbamazepine toxicity.
Aust N Z J Med.
1991;
21
886-887
-
9
Noda S, Umezaki H.
Carbamazepine-induced ophthalmoplegia.
Neurology.
1982;
32
1320
-
10
Spector R H, Davidoff R A, Schwartzman R J.
Phenytoin-induced ophthalmoplegia.
Neurology.
1976;
26
1031-1034
-
11
Crooks R, Mitchell T, Thom M.
Patterns of cerebellar atrophy in patients with chronic epilepsy: a quantitative neuropathological study.
Epilepsy Research.
2000;
41
63-73
-
12
Luef G, Burtscher J, Kremser C. et al .
Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.
European Neurology.
1996;
36
273-277
-
13
Ney G C, Lantos G, Barr W B, Schaul N.
Cerebellar atrophy in patients with long-term phenytoin exposure and epilepsy.
Archives of Neurology.
1994;
51
767-771
-
14
Leppik I E, Gram L, Deaton R. et al .
Safety of tiagabine: summary of 53 trials.
Epilepsy Research.
1999;
33
235-246
-
15
Karas B J, Wilder B J, Hammond E J. et al .
Treatment of valproate tremors.
Neurology.
1983;
33
1380-1382
-
16 Fisher R S, Kerigan J F. Vigabatrin Toxicity. In: Levy RH, Mattson RH, Meldum BS (eds) Antiepileptic Drugs. New York; Raven Press 1995: 985
-
17
Harrison M B, Lyons G R, Landow E R.
Phenytoin and dyskinesias: a report of two cases and review of the literature.
Movement Disorders.
1993;
8
19-27
-
18
van der Zwan A JR.
Transient Parkinson syndrome and tremor caused by the use of sodium valproate.
Ned Tijdschr Geneeskd.
1989;
133
1230-1232
-
19
Alvarez-Gomez M J, Vaamonde J, Narbona J. et al .
Parkinsonian syndrom in childhood after sodium valproat administration.
Clinical Neuropharmacology.
1993;
16
451-455
-
20
Onofrj M, Thomas A, Paci C.
Reversible parkinsonism induced by prolonged treatment with valproate.
J Neurol.
1998;
245
794-796
-
21
Armon C, Shin C, Miller P. et al .
Reversible parkinsonism and cognitive impairment with chronic valproate use.
Neurology.
1996;
47
626-635
-
22
Kurlan R, Kersun J, Behr J. et al .
Carbamazepine-induced tics.
Clinical Neuropharmacology.
1989;
12
298-302
-
23
Neglia J P, Glazen D G, Zion T E.
Tics and vocalizations in children treated with carbamazepine.
Pediatrics.
1984;
73
841-844
-
24
Robertson P L, Garofalo E A, Silverstein F S. et al .
Carbamazepine-induced tics.
Epilepsia.
1993;
34
965-968
-
25
Lombroso C T.
Lamotrigine-induced tourettism.
Neurology.
1999;
52
1191-1194
-
26
Menezes de Sotero A, Rho J, Murphy P. et al .
Lamotrigine-induced tic disorders: report of five pediatric cases.
Epilepsia.
2000;
41
862-867
-
27
Guerrini R, Belmonte A, Parmeggiani L. et al .
Myoclonic status epilepticus following high-dosage lamotrigine therapy.
Brain and Development.
1999;
21
420-424
-
28
Jacob P C, Chand R P, Omeima E.
Asterixis induced by gabapentin.
Clinical Neuropharmacology.
2000;
23
53
-
29
Rittmannsberger H, Leblhuber F.
Asterixis induced by carbamazepine therapy.
Biol Psychiatry.
1992;
32
364-368
-
30
Bodensteiner J B, Morris H H, Golden G S.
Asterixis associated with sodium valproate.
Neurology.
1981;
31
186-190
-
31
Duarte J, Sempere A P, Cabezas M C. et al .
Postural myoclonus induced by phenytoin.
Clinical Neuropharmacology.
1996;
19
536-538
-
32
Janszky J, Rásonyi G, Halász P. et al .
Disabling erratic myoclonus during lamotrigine therapy with high serum level - report of two cases.
Clinical Neuropharmacology.
2000;
23
86-89
-
33
Marciani M G, Maschio M, Spannedda F. et al .
Development of Myoclonus in patients with partial epilepsy during treatment with vigabatrin; an electroencephalographic study.
Acta Neurol Scand.
1995;
91
1-5
-
34
Asconape J, Diedrich A, DeallaBadia J.
Myoclonus associated with the use of gabapentin.
Epilepsia.
2000;
41
479-481
-
35
Evidente V G, Adler C H, Caviness J N. et al .
Effective treatment of orthostatic tremor.
Movement Disorders.
1998;
13
829-831
-
36
Onofrj M, Thomas A, Paci C. et al .
Gabapentin in orthostatic tremor: results of a double-blind cross-over with placebo in four patients.
Neurology.
1998;
51
880-882
-
37
Ondo W, Hunter C, Vuong K D. et al .
Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial.
Movement Disorders.
2000;
15
678-682
-
38
Pahwa R, Lyons K, Hubble J P. et al .
Double-blind controlled trial in essential tremor.
Movement Disorders.
1998;
13
465-467
-
39
Adler C H.
Treatment of restless legs syndrome with gabapentin.
Clinical Neuropharmacology.
1997;
20
148-151
-
40
Olson W L, Gruenthal M, Mueller M E. et al .
Gabapentin for parkinsonism: a double-blind, placebo-controlled, cross-over trial.
Am J Med.
1997;
102
60-66
-
41
Connor G S.
Topiramate as a novel treatment for essential tremor.
Movement Disorders.
1999;
14
908
-
42
Gálvez-Jimenéz N, Hargreave R N.
Topiramate and essential tremor.
Annals of Neurology.
2000;
47
837-838
-
43
Prevett M C, Brown P, Duncan J S.
Improvement of stiff-man syndrome with vigabatrin.
Neurology.
1997;
48
1133-1134
-
44
Vermeij F H, van Doorn P A, Busch H F.
Improvement of stiff-man syndrome with vigabatrin.
Lancet.
1996;
348
612
-
45
Shinotoh H, Vingerhoets F J, Lee C S. et al .
Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, cross-over study.
Neurology.
1997;
48
1282-1285
-
46
Zipp F, Burklin F, Stecker K. et al .
Lamotrigine in Parkinson's disease - a double-blind study.
J Neural Transm Park Dis Dement Sect.
1995;
10
199-206
-
47 Miller L G, Jankovic J. Drug-induced dyskinesias: an overview. In: Joseph A, Young R (eds) Movement Disorders in Neurology and Neuropsychiatry. Oxford; Blackwell 1999: 5-30
-
48
Sandyk R.
Total external ophthalmoplegia induced by phenytoin. A case report.
S Afr Med J.
1984;
65
141-142
Pascal Grosse
Neurologische Klinik und Poliklinik · Charité · Campus Virchow-Klinikum
Augustenburger Platz 1
13353 Berlin
